Neil Desai Sells 31,348 Shares of Aadi Bioscience, Inc. (NASDAQ:AADI) Stock

Aadi Bioscience, Inc. (NASDAQ:AADI) Chairman Neil Desai sold 31,348 shares of the business’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $1.45, for a total transaction of $45,454.60. Following the completion of the transaction, the chairman now owns 1,260,195 shares of the company’s stock, valued at $1,827,282.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Neil Desai also recently made the following trade(s):

• On Wednesday, May 1st, Neil Desai sold 40,000 shares of Aadi Bioscience stock. The stock was sold at an average price of $1.93, for a total transaction of $77,200.00.

Aadi Bioscience Stock Performance

Shares of AADI stock opened at $1.40 on Thursday. Aadi Bioscience, Inc. has a fifty-two week low of $1.28 and a fifty-two week high of $7.24. The firm has a market capitalization of $34.37 million, a price-to-earnings ratio of -0.55 and a beta of 0.69. The stock’s 50-day simple moving average is $1.77 and its 200-day simple moving average is $1.89.

Aadi Bioscience (NASDAQ:AADI) last issued its quarterly earnings results on Wednesday, May 8th. The company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.02). Aadi Bioscience had a negative return on equity of 61.83% and a negative net margin of 288.72%. The business had revenue of $5.35 million for the quarter, compared to analysts’ expectations of $6.41 million. As a group, equities analysts forecast that Aadi Bioscience, Inc. will post -2.54 earnings per share for the current year.

Institutional Investors Weigh In On Aadi Bioscience

A hedge fund recently bought a new stake in Aadi Bioscience stock. Decheng Capital LLC purchased a new position in shares of Aadi Bioscience, Inc. (NASDAQ:AADI) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 526,329 shares of the company’s stock, valued at approximately $1,063,000. Aadi Bioscience comprises about 0.3% of Decheng Capital LLC’s portfolio, making the stock its 22nd largest position. Decheng Capital LLC owned approximately 2.15% of Aadi Bioscience at the end of the most recent quarter. 52.08% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “neutral” rating on shares of Aadi Bioscience in a report on Tuesday, May 14th.

About Aadi Bioscience

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.